Revenue Breakdown
Composition ()
No data
Revenue Streams
Delcath Systems Inc (DCTH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HEPZATO KIT, accounting for 93.6% of total sales, equivalent to $19.25M. Another important revenue stream is CHEMOSAT. Understanding this composition is critical for investors evaluating how DCTH navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Delcath Systems Inc maintains a gross margin of 85.48%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.54%, while the net margin is -9.15%. These profitability ratios, combined with a Return on Equity (ROE) of 3.00%, provide a clear picture of how effectively DCTH converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, DCTH competes directly with industry leaders such as QTRX and TLSI. With a market capitalization of $310.28M, it holds a leading position in the sector. When comparing efficiency, DCTH's gross margin of 85.48% stands against QTRX's 26.04% and TLSI's N/A. Such benchmarking helps identify whether Delcath Systems Inc is trading at a premium or discount relative to its financial performance.
